https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00387-4/fulltext
0
0
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial - The Lancet
2/1/23 at 11:30pm
Organization
The Lancet
65 words
0
Comments
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
You are the first to view
Create an account or login to join the discussion